Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JKE1674
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JKE1674 is a small-molecule research compound that acts as an orally active inhibitor of glutathione peroxidase 4 (GPX4), a key enzyme that protects cells from ferroptosis (iron-dependent cell death). It is an active metabolite of the GPX4 inhibitor ML-210, featuring an α-nitroketoxime moiety in place of the nitroisoxazole ring found in ML-210. JKE1674 functions as a ferroptosis inducer and has demonstrated preclinical efficacy in various cancer models, including RB1-deficient prostate cancer and breast cancer. It is primarily used as a research tool and is available through various chemical reagent suppliers.
- Other names
- CAS 2421119-60-8CAS2421119-60-8CAS-2421119-60-8
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on JKE1674.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JKE1674.